Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.
暂无分享，去创建一个
E. Plimack | B. Melichar | B. Rini | F. Pouliot | B. Alekseev | T. Powles | Sterling Wu | R. McDermott | I. Vynnychenko | D. Soulières | L. R. Molife | D. Nosov | S. Tamada | T. Waddell | J. Burgents | D. Borchiellini | R. Gafanov | V. Stus | Jens Bedke | Sergio Jobim Azevedo | S. J. Azevedo